DDInter130 DDInter1269
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Atenolol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Atenolol {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Hepatic enzyme increased {u} (Side Effect) is caused by {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nateglinide
Atenolol {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Atenolol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Atenolol (Compound) resembles Sotalol (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Atenolol (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Atenolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Atenolol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Atenolol (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Atenolol (Compound) resembles Sotalol (Compound) and Sotalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nateglinide (Compound)
Atenolol (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide